HRP20010895A2 - Alpha v integrin receptor antagonists - Google Patents

Alpha v integrin receptor antagonists

Info

Publication number
HRP20010895A2
HRP20010895A2 HR20010895A HRP20010895A HRP20010895A2 HR P20010895 A2 HRP20010895 A2 HR P20010895A2 HR 20010895 A HR20010895 A HR 20010895A HR P20010895 A HRP20010895 A HR P20010895A HR P20010895 A2 HRP20010895 A2 HR P20010895A2
Authority
HR
Croatia
Prior art keywords
receptor antagonists
integrin receptor
alpha
present
antagonists
Prior art date
Application number
HR20010895A
Other languages
English (en)
Inventor
J Paul Coleman
E Mark Duggan
Wasyl Halczenko
George D Hartman
John H Hutchinson
S Robert Meissner
Michael A Patane
J James Perkins
Jiabing Wang
J Michael Breslin
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of HRP20010895A2 publication Critical patent/HRP20010895A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HR20010895A 1999-06-02 2001-11-30 Alpha v integrin receptor antagonists HRP20010895A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13710199P 1999-06-02 1999-06-02
US17921600P 2000-01-31 2000-01-31
PCT/US2000/014901 WO2000072801A2 (fr) 1999-06-02 2000-05-30 Antagonistes du recepteur de l'alpha v integrine

Publications (1)

Publication Number Publication Date
HRP20010895A2 true HRP20010895A2 (en) 2003-08-31

Family

ID=26834930

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010895A HRP20010895A2 (en) 1999-06-02 2001-11-30 Alpha v integrin receptor antagonists

Country Status (28)

Country Link
US (1) US6410526B1 (fr)
EP (1) EP1187592B1 (fr)
JP (3) JP3808707B2 (fr)
KR (1) KR20020021380A (fr)
CN (1) CN1589145A (fr)
AT (1) ATE368462T1 (fr)
AU (1) AU749351B2 (fr)
BG (1) BG106232A (fr)
BR (1) BR0011108A (fr)
CA (1) CA2373937A1 (fr)
CY (1) CY1107746T1 (fr)
CZ (1) CZ20014308A3 (fr)
DE (1) DE60035779T2 (fr)
DK (1) DK1187592T3 (fr)
DZ (1) DZ3263A1 (fr)
EA (1) EA200101272A1 (fr)
EE (1) EE200100642A (fr)
ES (1) ES2288861T3 (fr)
HR (1) HRP20010895A2 (fr)
HU (1) HUP0302468A2 (fr)
IL (1) IL146378A0 (fr)
IS (1) IS6157A (fr)
NO (1) NO323906B1 (fr)
PL (1) PL353364A1 (fr)
PT (1) PT1187592E (fr)
SK (1) SK17442001A3 (fr)
TR (1) TR200103431T2 (fr)
WO (1) WO2000072801A2 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
AU780988B2 (en) 2000-01-24 2005-04-28 Merck & Co., Inc. Alpha V integrin receptor antagonists
US6933304B2 (en) 2000-06-15 2005-08-23 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
JP2004504349A (ja) * 2000-07-26 2004-02-12 メルク　エンド　カムパニー　インコーポレーテッド αｖインテグリン受容体拮抗薬
WO2002022616A2 (fr) * 2000-09-14 2002-03-21 Merck & Co., Inc. Antagonistes du recepteur des integrines alpha v
WO2002028395A1 (fr) * 2000-10-04 2002-04-11 Merck & Co., Inc. Sel d'acide phosphorique tire d'un antagoniste d'un recepteur de l'integrine
JP2004517853A (ja) * 2001-01-03 2004-06-17 メルク　エンド　カムパニー　インコーポレーテッド 歯周病の治療方法及び治療用組成物
KR100861466B1 (ko) 2001-04-24 2008-10-02 메르크 파텐트 게엠베하 항혈관형성제 및 ＴＮＦα를 이용한 병용 요법
AU2003213682C1 (en) * 2002-03-04 2008-06-12 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin alphavbeta3 antagonist in combination with an HMG-CoA reductase inhibitor or a bisphosphonate
WO2003075957A1 (fr) * 2002-03-04 2003-09-18 Medimmune, Inc. Prevention ou traitement de cancer au moyen d'antagonistes de l'integrine alphavbeta3 combines a d'autres agents
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
US7115596B2 (en) 2002-12-20 2006-10-03 Pharmacia Corporation Thiazole compounds as integrin receptor antagonists derivatives
US7288655B2 (en) * 2003-03-07 2007-10-30 Merck & Co., Inc. α v integrin receptor antagonists
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
WO2007084670A2 (fr) 2006-01-18 2007-07-26 Merck Patent Gmbh Traitement specifique utilisant des ligands de l’integrine destine a traiter un cancer
EA017864B1 (ru) 2007-01-18 2013-03-29 Мерк Патент Гмбх Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака
TW200904437A (en) * 2007-02-14 2009-02-01 Janssen Pharmaceutica Nv 2-aminopyrimidine modulators of the histamine H4 receptor
EP2217238B1 (fr) 2007-11-08 2014-03-12 The General Hospital Corporation Procédés et compositions pour le traitement de maladies protéinuriques
JP2012528079A (ja) 2009-05-25 2012-11-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌を治療するためのインテグリンリガンドの連続投与
US8901144B2 (en) 2013-02-07 2014-12-02 Scifluor Life Sciences, Llc Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
KR102216091B1 (ko) * 2013-02-07 2021-02-16 사이플루어 라이프 사이언시즈, 인크 플루오르화 인테그린 길항제
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
EP4249471A3 (fr) 2013-09-24 2023-10-18 FUJIFILM Corporation Composition pharmaceutique d'un composé contenant de l'azote ou son sel ou son complexe métallique
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
AU2016219906B2 (en) * 2015-02-19 2020-10-01 Scifluor Life Sciences, Inc. Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
US10118929B2 (en) 2016-04-27 2018-11-06 Scifluor Life Sciences, Inc. Nonanoic and decanoic acid derivatives and uses thereof
WO2018009501A1 (fr) * 2016-07-05 2018-01-11 The Rockefeller University Antagonistes de l'intégrine tetrahydronaphthyridinepentanamide
EP3509590A4 (fr) 2016-09-07 2020-12-02 Pliant Therapeutics, Inc. Composés d'acides aminés n-acyle et méthodes d'utilisation
CN110167933B (zh) * 2016-11-08 2022-06-21 百时美施贵宝公司 作为αV整联蛋白抑制剂的唑酰胺和胺
JP7264810B2 (ja) * 2016-11-08 2023-04-25 ブリストル－マイヤーズ スクイブ カンパニー アルファｖインテグリン阻害剤としてのシクロブタン－およびアゼチジン－含有の単環およびスピロ環式化合物
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
EP3589627A4 (fr) 2017-02-28 2020-08-05 Morphic Therapeutic, Inc. Inhibiteurs de l'(alpha-v)(bêta-6) intégrine
PE20211640A1 (es) 2018-08-29 2021-08-24 Morphic Therapeutic Inc INHIBICION DE LA INTEGRINA xvß6

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3843798A (en) 1973-03-12 1974-10-22 Stanley Drug Products Inc Methods and compositions for inducing resistance to bacterial infections
US5025025A (en) 1989-06-28 1991-06-18 Ciba-Geigy Corporation (Arylsulfonamido- and pyridyl-)-substituted carboxylic acids and derivatives thereof and use for suppressing thromboxane activity
WO1992019595A1 (fr) 1991-05-07 1992-11-12 Merck & Co., Inc. Antagonistes de recepteur de fibrinogene
DE69222433D1 (de) 1991-11-22 1997-10-30 Yeda Res & Dev Nicht-peptidische surrogate der arg-gly-asp sequenz und entsprechende pharmazeutische zusammensetzungen
US5786373A (en) 1992-10-14 1998-07-28 Merck & Co., Inc. Fibrinogen receptor antagonists
AU701776B2 (en) 1994-05-27 1999-02-04 Merck & Co., Inc. Compounds for inhibiting osteoclast-mediated bone resorption
AU713676B2 (en) 1996-01-16 1999-12-09 Merck & Co., Inc. Integrin receptor antagonists
DE59706273D1 (de) 1996-03-20 2002-03-21 Hoechst Ag Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
EP0901373B1 (fr) 1996-04-10 2002-11-06 Merck & Co., Inc. ANTAGONISTES DU RECEPTEUR Alpha v Beta 3
US5668159A (en) 1996-05-08 1997-09-16 The Dupont Merck Pharmaceutical Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as IIb/IIIa antagonists
AU724191B2 (en) 1996-08-29 2000-09-14 Merck & Co., Inc. Integrin antagonists
DE69720771T2 (de) * 1996-10-30 2004-01-29 Merck & Co Inc Integrin antagonist
EP0946164A4 (fr) 1996-10-30 2000-08-23 Merck & Co Inc Antagonistes de l'integrine
JP2001509176A (ja) 1997-01-17 2001-07-10 メルク エンド カンパニー インコーポレーテッド インテグリンアンタゴニスト
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
AU736026B2 (en) 1997-12-17 2001-07-26 Merck & Co., Inc. Integrin receptor antagonists
US6017926A (en) 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
KR20010033248A (ko) * 1997-12-17 2001-04-25 폴락 돈나 엘. 인테그린 수용체 길항제
EP1044001B1 (fr) 1997-12-17 2005-07-06 Merck & Co., Inc. Antagonistes du recepteur de l'integrine
WO1999031099A1 (fr) 1997-12-17 1999-06-24 Merck & Co., Inc. Antagonistes du recepteur de l'integrine

Also Published As

Publication number Publication date
NO323906B1 (no) 2007-07-16
EP1187592B1 (fr) 2007-08-01
PL353364A1 (en) 2003-11-17
EE200100642A (et) 2003-02-17
IL146378A0 (en) 2002-07-25
CY1107746T1 (el) 2013-04-18
JP2004500326A (ja) 2004-01-08
NO20015858L (no) 2002-02-04
ATE368462T1 (de) 2007-08-15
DE60035779D1 (de) 2007-09-13
DZ3263A1 (fr) 2000-12-07
IS6157A (is) 2001-11-13
BR0011108A (pt) 2002-03-19
HUP0302468A2 (hu) 2003-11-28
EP1187592A2 (fr) 2002-03-20
JP2006232844A (ja) 2006-09-07
CN1589145A (zh) 2005-03-02
KR20020021380A (ko) 2002-03-20
US6410526B1 (en) 2002-06-25
AU5724600A (en) 2000-12-18
WO2000072801A3 (fr) 2007-10-11
SK17442001A3 (sk) 2002-03-05
PT1187592E (pt) 2007-10-19
DE60035779T2 (de) 2008-04-30
JP3808707B2 (ja) 2006-08-16
CZ20014308A3 (cs) 2002-03-13
ES2288861T3 (es) 2008-02-01
JP2006206604A (ja) 2006-08-10
WO2000072801A2 (fr) 2000-12-07
BG106232A (en) 2002-06-28
NO20015858D0 (no) 2001-11-30
EP1187592A4 (fr) 2002-11-06
AU749351B2 (en) 2002-06-27
CA2373937A1 (fr) 2000-12-07
DK1187592T3 (da) 2007-11-05
TR200103431T2 (tr) 2002-06-21
EA200101272A1 (ru) 2002-06-27

Similar Documents

Publication Publication Date Title
IL146378A0 (en) Alpha v integrin receptor antagonists
DE69720771D1 (en) Integrin antagonist
PL341095A1 (en) Compounds acting as antagonists of integrin receptor
DE69829996D1 (de) Integrin-rezeptor-antagonisten
EP1044001A4 (fr) Antagonistes du recepteur de l'integrine
ES2185009T3 (es) Antagonistas de alfa y beta 3'.
AU7793501A (en) Alpha v integrin receptor antagonists
WO2002090325A3 (fr) Benzazepinones, antagonistes de recepteur d'integrine alpha v
AU3943502A (en) Dibenzoxazepine alpha v integrin receptor antagonist
YU38200A (sh) Antagonisti integrinskog receptora
YU38300A (sh) Antagonisti integrinskog receptora

Legal Events

Date Code Title Description
A1OB Publication of a patent application
OBST Application withdrawn